印度首次推出本土抗生素Nafithromycin, 并成功治疗血友病的基因疗法。 India launches its first homegrown antibiotic, Nafithromycin, and achieves gene therapy success for hemophilia.

印度开发了第一种完全本土抗生素 -- -- Nafithromycin,有效防治抗药性肺感染,特别有益于癌症病人和无控制的糖尿病患者。 India has developed its first fully indigenous antibiotic, Nafithromycin, effective against drug-resistant lung infections and particularly beneficial for cancer patients and those with uncontrolled diabetes. 该药在印度经过构思、研制和临床验证,标志着在药物自食其力方面迈出了重大一步。 The drug, conceived, developed, and clinically validated in India, marks a major step in pharmaceutical self-reliance. 印度在血友病基因治疗方面也取得了突破,在《新英格兰医学杂志》上公布的一项试验显示,有60%至70%的矫正率,没有出血病例。 India also achieved a breakthrough in gene therapy for hemophilia, with a trial showing 60–70% correction and no bleeding episodes, published in the New England Journal of Medicine. 已经对10 000多个人类基因组进行了测序,目标是100万个。 Over 10,000 human genomes have been sequenced, with a goal of one million. Anusandhan国家研究基金会支持创新,支持的五年计划资金为5万格朗,私人提供大量资金。 The Anusandhan National Research Foundation, backed by a ₹50,000 crore five-year plan with significant private funding, supports innovation. 包括流动诊所和冤情投诉系统在内的保健方面的AI一体化正在推动病人的护理。 AI integration in healthcare, including mobile clinics and grievance systems, is advancing patient care.